Archives of General Psychiatry, 1962; 6 (203-213)
Archive of information on the use of psychoactive drugs.
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Psychotomimetic Drugs, 1970; pp. 265-273
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
In the children's unit of Creedmore State Hospital with a resident population of 450 patients, ages 4 to 15, we have investigated the responses of some of these children to lysergic acid and related drugs in the psychiatric, psychological and biochemical areas. Two groups of boys receiving daily LSD, UML (which is a methylated derivative of LSD) or psilocybin ... at first the medication was given weekly but was eventually given daily for periods of up to several months. Dosages remain constant throughout, LSD 150 mcg. (which is a standard for an adult trip), psilocybin 20 mg. daily or UML 12 mg. daily, all given in two divided doses. The average duration of treatment was 2 to 3 months. Daily. Children, 7, 9 , 11 years old ...
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Diseases of the Nervous System, 27:43-46 1966
(LSD) aroused the interest of many psychiatrists who were in no sense cultural rebels or especially radical in their attitudes. It was recommended for a wide variety of problems including alcoholism, obsessional neurosis, and childhood autism.
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Recent Advances in Biological Psychiatry, 5:84-92, 1963
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
American Druggist, 146 (13):33, 1962
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
American Journal of Psychiatry, May 1966, pp. 1201-1211
James Q. Simmons III, O. Ivar Lovaas, et al
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Archives of General Psychiatry 25: 498-510
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Acta paedopsychiatrica, 34:298-307, 1968
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Recent Advances in Biological Psychiatry, 1962; 4:170-77
Now that the FDA has permitted research with LSD and psilocybin to resume, we feel it is important to share examples of a remarkable experiment, the results of which were not sufficiently taken into account because this line of research was prematurely halted in the mid-sixties due to political considerations. Childhood schizophrenia is still a difficult problem to treat and causes much suffering. It is a terrible shame that research done 35 years ago is still the last word on the use of psychedelics to treat these conditions.
Gary Fischer, Newsletter of the Multidisciplinary Association for Psychedelic Studies
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Biological Treatment of Mental Illness, Proceedings II of the International Conference of the Manfred Sakel Foundation 10/31-11/3/1962, 1966; 2(4):463-91
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Journal of Asthma Research, 5: 139-143 (1967)
href="http://www.neurodiversity.net
href="http://www.neurodiversity.net
Behavioral Neuropsychiatry 1969 Nov;1(8):44-50
Robert E. Mogar, Robert W. Aldrich